FDA says all ranitidine drugs should be recalled on safety concernsThe FDA has asked drugmakers to pull all prescription and over-the-counter products based on ranitidine off the market Share XFDA says all ranitidine drugs should be recalled on safety concernshttps://pharmaphorum.com/news/fda-says-all-ranitidine-drugs-should-be-recalled-on-safety-concerns/
Amarin hit hard as generics loom for fish oil drug VascepaGeneric drugmakers Hikma and Dr Reddy’s Laboratories have won a surprise victory in a US patent lawsuit that Share XAmarin hit hard as generics loom for fish oil drug Vascepahttps://pharmaphorum.com/news/amarin-hit-hard-as-generics-loom-for-fish-oil-drug-vascepa/
CHMP backs safety of anticoagulants after real-world studyThe EMA’s human drugs advisory committee has said that no change is needed to the use of direct Share XCHMP backs safety of anticoagulants after real-world studyhttps://pharmaphorum.com/news/chmp-backs-safety-of-anticoagulants-after-real-world-study/
Ogilvy Health promotes Ripal Patel to CFOOgilvy Health has promoted Ripal Patel from SVP, client financial services to chief financial officer (CFO). Patel has Share XOgilvy Health promotes Ripal Patel to CFOhttps://pharmaphorum.com/sales-marketing/ogilvy-health-promotes-ripal-patel-to-cfo/
Golin makes Ondine Whittington group managing directorOndine Whittington has been promoted to group managing director for Golin and Virgo Health London. Previously managing director Share XGolin makes Ondine Whittington group managing directorhttps://pharmaphorum.com/news/golin-virgo-health-ondine-whittington/
Avenir Global appoints Miranda Dini global healthcare leadAvenir Global has appointed Miranda Dini as global healthcare lead, adding to her ongoing leadership of the communications Share XAvenir Global appoints Miranda Dini global healthcare leadhttps://pharmaphorum.com/news/avenir-global-miranda-dini-healthcare/
Is Neil Woodford planning an audacious comeback?Just a few months after the collapse of his troubled investment fund, Neil Woodford is reported to be Share XIs Neil Woodford planning an audacious comeback?https://pharmaphorum.com/news/is-neil-woodford-planning-an-audacious-comeback/
‘Predatory’ drugmakers exploit FDA’s unapproved drug scheme; studyAn FDA mechanism designed to curb unapproved uses of medicines could be encouraging pharma companies to implement massive Share X‘Predatory’ drugmakers exploit FDA’s unapproved drug scheme; studyhttps://pharmaphorum.com/news/predatory-drugmakers-exploit-fdas-unapproved-drug-scheme-study/
MicroMass hires Rosanne Johnson as executive vice presidentPharmaceutical marketing agency MicroMass Communications has named Rosanne Johnson as its new executive vice president. In her role, Share XMicroMass hires Rosanne Johnson as executive vice presidenthttps://pharmaphorum.com/sales-marketing/micromass-hires-rosanne-johnson-as-executive-vice-president/
Pharma industry body urges “ambition” in UK-EU trade talksA pharma industry group has welcomed the UK’s priorities in trade talks due to start with the EU Share XPharma industry body urges “ambition” in UK-EU trade talkshttps://pharmaphorum.com/market-access-2/pharma-industry-body-urges-ambition-in-uk-eu-trade-talks/
Podcast series to spotlight health heroes launched by KantarA new pharmaceutical podcast putting health heroes in the spotlight debuts in the runup to Rare Diseases Day Share XPodcast series to spotlight health heroes launched by Kantarhttps://pharmaphorum.com/news/podcast-series-to-spotlight-health-heroes-launched-by-kantar/
Mallinckrodt proposes $1.6bn deal to settle opioid litigationMallinckrodt is placing a $1.6 billion settlement package on the table as it tries to bring litigation related Share XMallinckrodt proposes $1.6bn deal to settle opioid litigationhttps://pharmaphorum.com/news/mallinckrodt-proposes-1-6bn-deal-to-settle-opioid-litigation/
Diversity initiative DICE launches to tackle conference inclusionDICE, a coalition of marketing industry figures, has launched to improve diversity and inclusion at conference and events. Share XDiversity initiative DICE launches to tackle conference inclusionhttps://pharmaphorum.com/news/marketing-conference-diversity-initiative-dice/
performance-io appoints Amy de la Force as executive creative directorLondon-based health-tech performance marketing agency performance-io has expanded, forming a new creative department and recruiting Amy de la Share Xperformance-io appoints Amy de la Force as executive creative directorhttps://pharmaphorum.com/news/performance-io-amy-de-la-force/
Cello Health Insight brings Breaking Blue into the foldCello Health has merged its global tech and consumer research business Breaking Blue Research with its Cello Health Share XCello Health Insight brings Breaking Blue into the foldhttps://pharmaphorum.com/news/cello-health-insight-breaking-blue-research/
Blockbusters in waiting: drug launches to watch in 2020New drugs for breast cancer, lymphoma, multiple sclerosis and migraine are among new product launches this year that Share XBlockbusters in waiting: drug launches to watch in 2020https://pharmaphorum.com/news/blockbusters-in-waiting-drug-launches-to-watch-in-2020/
ICER methods could be illegal in US, claims US think tankThe method used by the US Institute for Clinical and Economic Review (ICER) to gauge whether drugs are Share XICER methods could be illegal in US, claims US think tankhttps://pharmaphorum.com/news/icer-methods-could-be-illegal-in-us-claims-us-think-tank/
Woodford biotech ‘fire-sale’ looms after rescue bid fails; reportA proposed deal to buy up a portfolio of biotechs in Neil Woodford’s collapsed investment fund has fallen Share XWoodford biotech ‘fire-sale’ looms after rescue bid fails; reporthttps://pharmaphorum.com/news/woodford-biotech-fire-sale-looms-after-rescue-bid-fails-report/
